

Optimized assays for accompanying the various FVIII and FIX



- Homogenous reactivity of chromogenic assays with the various existing and new blood extracted, recombinant (regardless the structure), and long acting (pegylated, glycopegylated, or Fc/albumin fusion proteins) products.
- Use of a single calibrator, established against the WHO International Standards (NIBSC, Potters Bar, UK).
- Reliable & robust assays designed with only human highly purified factors
- Validated method applications for the various major laboratory instruments.

© Can Stock Photo Innodkeybusiness

BIOPHEN™ FVIII:C	RUO	Ref.	Presentation
		A221402-RUO	2 x 2.5 mL
		A221406-RUO	2 x 6 mL

Chromogenic assay for measuring Factor VIII:C activity in human citrated plasma or in Factor VIII:C therapeutic concentrates.

- Working range : 0.25 – 250 %
- Insensitive to presence of lupus-like anticoagulant¹ and Heparin.
- Validated applications for ACL TOP, BCS XP, CS & STA-R.

ZYMUTEST™ Anti VIII IgG Monostrip IgG -Isotype	RUO	Ref.	Presentation
		ARK039A-RUO-MIN	32 tests

Measurement of FVIII:C antibodies by ELISA

HEMOCLOT™ Factor VIIa	RUO	Ref.	Presentation
		ACK092K-RUO	3 x 2 mL

Clotting assay for quantitative measurement of activated Factor VII activity in human citrated plasma or in Factor VIIa therapeutic concentrates.

- Applications on CS & STA-R.

BIOPHEN™ Factor IX	RUO	Ref.	Presentation
		A221802-RUO	2 x 2.5 mL
		A221806-RUO	2 x 6 mL

Chromogenic assay for measuring Factor IX activity in human citrated plasma or in Factor IX therapeutic concentrates.

- Working range : 0.75 – 250 %
- Insensitive to presence of Heparin.
- Recommended for testing Factor IX with recombinant products.²
- Validated applications for ACL TOP, BCS XP, CS & STA-R.

Visit our website www.aniara.com for more information

References:

¹De Maistre E, Wahl D, Perret-Guillaume C, Regnault V, Clarac S, Briquel ME, et al. A chromogenic assay allows reliable measurement of factor VIII levels in the presence of strong lupus anticoagulants. *Thromb Haemost. Janv 1998;79(1):237-238.*

²Kitchen S, Gray E, Mertens K. Monitoring of modified factor VIII & IX products. *Haemophilia 2014, 20 – 36-42.*